Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

Affiliations

• ¹ Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
• ² Penn State College of Medicine, Hershey, Pennsylvania, USA.
• ³ Department of Pathology, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
• ⁴ Gerstner Sloan-Kettering Graduate School in Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
• ⁵ Department of Biostatistics and Computational Biology, Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁶ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA, and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
• ⁷ Leukemia Service, Memorial Sloan-Kettering Cancer Center, NY, USA.
• ⁸ Institute of Molecular Cancer Research, University of Zurich, Zurich Switzerland laura.devargasroditi@uzh.ch.